Xsolla Expands Mobile and Digital Distribution Solution Offerings and Adds an NFT Checkout to the Growing Set of Tools and Services for Developers
28.4.2022 11:06:00 EEST | Business Wire | Press release
Xsolla, a global video game commerce company, announced today that it has expanded their mobile and digital distribution solutions to provide more opportunities for developers to launch and grow their games around the world. In addition, Xsolla has added a new checkout feature to help developers scale their brands by selling and distributing NFTs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220428005554/en/
XSOLLA EXPANDS MOBILE AND DIGITAL DISTRIBUTION SOLUTION OFFERINGS AND ADDS AN NFT CHECKOUT TO THE GROWING SET OF TOOLS AND SERVICES FOR DEVELOPERS (Graphic: Business Wire)
“Xsolla is committed to providing best-in-class services and support for developers worldwide to help them reach more players in more geographies,” stated Chris Hewish, President of Xsolla. “We continue to develop new features that target the key challenges of marketing, launching, and monetizing video games. We have more to come in 2022 that will keep our partners ahead of the constantly evolving game climate.”
Mobile Web Shop - New Features
As the expanding mobile landscape continues to lead global gaming revenue, Xsolla’s Web Shop for Mobile Games has added new features to help mobile developers to reach more players and to remain at the forefront of the mobile gaming revolution.
● Expanded Analytics
Developers can create a transparent funnel that will increase efficiency in bringing new players to their Web Shop. This will help developers understand the player experience online and determine where and how users engage with their game.
● Unique Promotions
This built-in component helps developers benefit from in-app purchases through their Web Shop. Within the online experience, developers can provide promotional offers and launch discount campaigns, promo code offers, and bonuses to boost sales and bring new players online.
● Subscriptions Management
To help developers sell a complete catalog of digital goods in their Web Shop, Xsolla added robust subscription features. This allows developers to gain and retain new customers, create loyalty, generate reliable revenue streams, and manage subscriptions with confidence.
For more information about the Xsolla Web Shop, visit: https://xsolla.com/solution/web-shop-for-mobile-games
NFT Checkout
Xsolla has created an NFT Checkout process to allow developers to quickly and securely add NFTs to their game economy. This feature enables players to make purchases using their preferred payment method. The developer handles the minting and the delivery of the NFTs, while Xsolla handles the checkout and in-game items distribution process.
For more details about NFT Checkout, visit: https://xsolla.com/solution/payments/nft-checkout
Digital Distribution Hub
Xsolla Digital Distribution Hub connects games to a global network of apps, internet service providers (ISPs), banks, and other channels to help developers reach players and gain revenue from every transaction. This new solution empowers gamers to discover and support their favorite games through an optimized multi-platform experience and allows them to pay how and when they want.
Developers can now benefit from increased market penetration and brand awareness through distribution channels, such as super apps, online banking apps and mobile carrier marketplaces. With the Digital Distribution Hub your game can reach a vast audience of new users, save on distribution costs, and boost overall revenue and engagement.
To learn more about Digital Distribution Hub, visit: https://xsolla.com/products/digital-distribution-hub
Xsolla will present these solutions and more at several upcoming events, including GamesBeat Summit 2022, Pocket Gamer Connects Seattle, Nordic Game Show, Pocket Gamer Toronto, China Joy, and gamescom, in the next six months. Register to meet up with the experts at Xsolla by visiting: https://xsolla.com/events.
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the video game industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Berlin, Seoul, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Roblox, Ubisoft, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005554/en/
Contact information
Derrick Stembridge
Director of Public Relations, Xsolla
d.stembridge@xsolla.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom